REPAGLINIDE | A203820 | AUROBINDO PHARMA LTD
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
| D.N.J. | 2012-02-16 | Terminated 2012-04-10 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$0.0917
per ea
Lowest NADAC/Unit
$0.0761
per ea
Brand NDCs
0
Generic NDCs
7
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 57237015901REPAGLINIDE 2 MG TABLET | $0.0917 | EA | Generic | — | 2026-06-17 |
| 65862067201REPAGLINIDE 2 MG TABLET | $0.0917 | EA | Generic | — | 2026-06-17 |
| 60687056021REPAGLINIDE 1 MG TABLET | $0.0887 | EA | Generic | — | 2026-06-17 |
| 57237015801REPAGLINIDE 1 MG TABLET | $0.0887 | EA | Generic | — | 2026-06-17 |
| 65862067101REPAGLINIDE 1 MG TABLET | $0.0887 | EA | Generic | — | 2026-06-17 |
| 57237015701REPAGLINIDE 0.5 MG TABLET | $0.0761 | EA | Generic | — | 2026-06-17 |
| 65862067001REPAGLINIDE 0.5 MG TABLET | $0.0761 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.